Healthcare Industry News: NEOPHARM
News Release - June 22, 2006
NeoPharm Announces Appointment of Vice-President of Regulatory Affairs and Quality Assurance
WAUKEGAN, Ill.--(HSMN NewsFeed)--June 22, 2006--NEOPHARM, Inc. (Nasdaq:NEOL ) today announced that it has appointed biotechnology and pharmaceutical industry veteran John H. Waterman as the Company's new Vice President of Regulatory Affairs and Quality Assurance.Mr. Waterman has more than 20 years of progressively responsible regulatory affairs and quality assurance management experience at firms specializing in research, development, and marketing of pharmaceuticals, devices and high-technology healthcare products for nuclear medicine, and cancer therapeutics. Mr. Waterman most recently served as the Vice President of Regulatory Affairs and Quality Assurance with MGI Pharma. Mr. Waterman holds a BA in Biology from Hope College in Holland, Michigan, and a Masters of Science from the Stuart Graduate School of Business from the Illinois Institute of Technology in Chicago, Illinois.
NEOPHARM's Commitment to Oncology
NEOPHARM employees share a common goal: bringing hope to cancer patients and their families through the research and development of new cancer drugs and therapies. The Company's oncology portfolio is built on two novel, proprietary platforms: a tumor-targeting platform, and the NeoLipid® Liposomal Drug Delivery platform. Through its research and clinical studies, as well as its work with physicians, scientists, and advocacy groups, NEOPHARM is helping to enhance the lives of cancer patients.
About NEOPHARM, Inc.
NEOPHARM, Inc., based in Waukegan, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. Additional information, including ongoing clinical trials, can be obtained by visiting NEOPHARM's Web site at www.NEOPHARM.com.
Forward Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company's ability to recruit and retain qualified personnel, and any other statements that are not historical facts. Such statements involve risks and uncertainties detailed from time to time in filings the Company makes with the Securities and Exchange Commission including its annual reports on Form 10-K and quarterly reports on Forms 10-Q. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on these forward-looking statements as a prediction of actual future results.
Source: NeoPharm
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!